Skip to NavigationSkip to content

AstraZeneca announces price freezes while earnings drop by 28%

Published on 26/07/18 at 10:26am
AstraZeneca building with logo

The Anglo-Swedish drug maker AstraZeneca has joined Pfizer and others in halting price hikes until the end of 2018.

AstraZeneca Chief Executive Pascal Soriot announced that the company would match commitments made by Pfizer, Novartis, Roche and Merck stating that: “There is a clear commitment in the company to not increase prices in the second half of the year.”

However the announcement comes as the multinational firm declared that second quarter earnings had dropped by 28%. The loss of earning has been linked to the reduction in sales of the cholesterol treatment Crestor, which declined by 40%, as the drug lost patent protection in Europe and Japan.

The move comes as Trump’s campaign against constant price hikes takes hold. Nevertheless, although Trump made lowering drug prices a major campaign issue in 2016, the recent price freezes have come into question, as critics suggest that they may not be as meaningful as they appear. While observers noted that MSD’s price reductions were on already unprofitable drugs, it was pointed out that Roche had announced their price freezes immediately after hiking prices by an average of 3%.

As such the real impact is yet to be seen. Analysts have suggested that the 2018 price freezes could provide additional leeway for higher price hikes next year.

Louis Goss


good one .. 

Wow it's s good news these two companies are going to work together now. Recently I have read an article in the best essay writing services stating the prices of the drugs are very high when the two companies are separated now they decided to reduce the cost of the drugs so that it can be affordable by people. This is a really good initiative as everyone can afford it now. They also mentioned that the hikes of these companies increased more now.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches